Browsing by Author "Chotipong Siripipattanamongkol"

Filter results by typing the first few letters
Now showing 1 - 1 of 1
  • No Thumbnail Available
    PublicationMetadata only
    Real-world effectiveness and safety of sofosbuvir and nonstructural protein 5A inhibitors for chronic hepatitis C genotype 1, 2, 3, 4, or 6: A multicentre cohort study
    (2020-03-05) Phunchai Charatcharoenwitthaya; Virasak Wongpaitoon; Piyawat Komolmit; Wattana Sukeepaisarnjaroen; Pisit Tangkijvanich; Teerha Piratvisuth; Theeranun Sanpajit; Chinnavat Sutthivana; Chalermrat Bunchorntavakul; Abhasnee Sobhonslidsuk; Soonthorn Chonprasertsuk; Chotipong Siripipattanamongkol; Supatsri Sethasine; Tawesak Tanwandee; Chulalongkorn University; Bhumibol Adulyadej Hospital; Bumrungrad International Hospital; Vajira Hospital; Khon Kaen University; Faculty of Medicine, Ramathibodi Hospital, Mahidol University; Thammasat University; Faculty of Medicine, Siriraj Hospital, Mahidol University; Phramongkutklao College of Medicine; Prince of Songkla University; Rajavithi Hospital; Chiangrai Prachanukroh Hospital
    © 2020 The Author(s). Background: We investigated real-world effectiveness and safety of sofosbuvir and the nonstructural protein 5A inhibitors in the treatment of patients infected with hepatitis C virus (HCV) genotypes 1, 2, 3, 4, or 6. Methods: We analyzed data from 1021 patients with HCV infection (506 with genotype 1; 16 with genotype 2; 314 with genotype 3; 13 with genotype 4; 166 with genotype 6) who received 12 to 24 weeks of daclatasvir plus sofosbuvir (n = 767), ledipasvir/sofosbuvir (n = 197), or sofosbuvir/velpatasvir (n = 57), with or without ribavirin in 12 centers across Thailand to estimate sustained virologic response at post-treatment week 12 (SVR12). Results: Overall, SVR12 rate was 98.0% (95% confidence interval [CI], 96.7-98.8%) with daclatasvir plus sofosbuvir, 97.9% (95% CI, 94.8-99.2%) with ledipasvir/sofosbuvir, and 96.5% (95% CI, 88.1-99.0%) with sofosbuvir/velpatasvir. SVR12 was achieved by 99.2% (95% CI, 97.9-99.7%) of subjects with genotype 1 infection, 100% (95% CI, 78.5-100%) of those with genotype 2 infection, 96.7% (95% CI, 94.0-98.2%) of those with genotype 3 infection, 90.9% (95% CI, 62.3-98.4%) of those with genotype 4 infection, and 96.7% (95% CI 92.5-98.6%) of those with genotype 6 infection. Patients with advanced liver disease were at risk of treatment failure. Only four patients discontinued treatment before week 4 due to non-hepatic adverse events. Conclusions: In this large cohort of patients with various HCV genotypes managed in the real-world practice setting, daclatasvir plus sofosbuvir, ledipasvir/sofosbuvir, and sofosbuvir/velpatasvir achieved high SVR rates with good safety profile, comparable to those observed in clinical trials.